Litigation Details for Azurity Pharmaceuticals, Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 2023)

Azurity Pharmaceuticals, Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 2023)

Docket		Date Filed	2023-09-29
Court	District Court, D. Delaware	Date Terminated	2024-05-14
Cause	35:1 Patent Infringement	Assigned To	Maryellen Noreika
Jury Demand	None	Referred To
Patents	7,157,584; 7,572,920; 9,066,936; 9,169,238; 9,387,249
Link to Docket	External link to docket

Details for Azurity Pharmaceuticals, Inc. v. Teva Pharmaceuticals, Inc. (D. Del. 2023)

Date Filed	Document No.	Description	Snippet	Link To Document
2023-09-29				External link to document

Azurity Pharmaceuticals v. Teva (1:23-cv-01080): Litigation Summary, Claims at Issue, Procedural Posture, and Competitive Impact

Last updated: June 12, 2026

Executive summary: In Azurity Pharmaceuticals, Inc. v. Teva Pharmaceuticals, Inc., No. 1:23-cv-01080, filed in 2023, Azurity asserts US patent infringement against Teva tied to an FDA-regulated drug product. The litigation is a standard Hatch-Waxman-style enforcement case in which the plaintiff typically challenges a generic or proposed generic entry and seeks damages and/or injunctive relief. The case materially affects US timing and launch risk for Teva and any downstream partners, and it signals that Azurity’s Orange Book-linked patent estate remains active and asserted in federal court.

What patents are at issue, and what does Azurity accuse Teva of? Azurity’s infringement theory in this matter follows the Hatch-Waxman pattern: Azurity (as branded NDA holder and/or patent owner) alleges that Teva’s proposed product filing, manufacturing, and/or market conduct infringes one or more Orange Book-listed patents. In these cases, claims usually center on one or more of the following buckets:

• Drug substance patents: claims directed to the active ingredient or its preparation.
• Formulation or dosage-form patents: claims directed to specific compositions, ratios, release profiles, particle properties, or excipient systems.
• Method-of-use patents: claims directed to treatment regimens, indications, or dosing steps tied to label-approved uses.
• Manufacturing-process patents: claims directed to specific process steps for producing the drug product.

Practical litigation impact of claim type

• Formulation and dosage-form claims are often the most litigation-intensive because generic manufacturers may attempt “design-around” by changing composition, manufacturing parameters, or dosage form attributes.
• Method-of-use claims force a label carve-out strategy. If Teva’s product challenges a method-of-use patent, the dispute can hinge on FDA labeling language and Teva’s ability to omit patented instructions.
• Drug substance and process claims can constrain the supply chain because Teva’s API source and manufacturing route become part of the infringement record.

Key detail for business decisions: the economic exposure is driven by whether Azurity’s asserted claims map to the scope of Teva’s FDA ANDA product (formulation/strength/dosing) and whether Teva’s non-infringement or invalidity defenses plausibly undercut the entire asserted set or only a subset.

---

Where is the case filed, and what court handles it? This case is docketed as 1:23-cv-01080 and is styled Azurity Pharmaceuticals, Inc. v. Teva Pharmaceuticals, Inc. The “1:” prefix indicates US District Court case numbering. These disputes proceed under the federal patent infringement framework (35 USC § 271) and, in Hatch-Waxman contexts, are structured around Orange Book listings and the statutory pathways implicated by an ANDA.

Why the court and venue matter for leverage

• District court decisions can shape settlement posture through early rulings on claim construction, stay motions, and infringement/invalidity viability.
• Claim construction outcomes often determine whether parties move toward licensing/settlement or continue to trial.

---

What is the procedural posture in Azurity v. Teva (1:23-cv-01080)? Without the docket text and filings, no reliable determination can be made about dates of Markman, claim construction, dispositive motion deadlines, trial scheduling, or whether the parties settled and/or entered an injunction. Patent cases like this typically follow these milestones:

• Complaint and service
• Initial responsive pleadings
• Early claim construction or scheduling order
• Motions to dismiss or for summary judgment (often invalidity and non-infringement)
• Discovery and expert reports
• Daubert rulings (where contested)
• Injunction or damages-phase progression if liability is found

Business relevance: Teva’s launch timing and risk profile depend on whether the case is stayed, whether a preliminary injunction is sought and decided, and whether the case targets an early-dispositive invalidity theory that could clear the path to generic entry.

---

Is this tied to an ANDA Paragraph IV filing, and what does that imply? Most branded-vs-generic patent suits labeled with an Orange Book patent dispute are connected to an ANDA filing with a Paragraph IV certification (or some related certification posture). In that scenario:

• Azurity identifies specific Orange Book patents.
• Teva asserts non-infringement and/or invalidity.
• The 30-month stay can apply depending on FDA approval timing and the nature of the litigation.

Commercial implication: If Azurity’s asserted patents include at least one that is upheld or not successfully invalidated, Teva can lose launch timing. If a court narrows or invalidates key claims, the generic product can enter earlier, with knock-on effects on competing ANDA filers.

---

When does exclusivity end, and how does litigation affect Teva’s launch window? In Hatch-Waxman cases, launch timing depends on the overlap of:

• Patent expiration (including any pediatric exclusivity where applicable)
• Regulatory exclusivities (data exclusivity, 505(b)(2) exclusivity where applicable)
• 30-month stay effect (if applicable)
• Court outcomes on infringement and validity
• Any settlement agreement with a negotiated “carve-out” date

Business relevance: Absent a disclosed settlement date or final judgment, litigation creates a value transfer risk for both sides. For investors and planners, the key is whether the case is likely to resolve before the likely expiration of the relevant patents and whether a negotiated settlement locks in a later entry date.

---

What does the case say about the strength of Azurity’s patent estate? A branded company files these suits when it has at least one of the following:

• An Orange Book-listed patent that it believes is infringed by the proposed generic product.
• Claims that can survive early challenges under claim construction and invalidity standards.
• A licensing or settlement objective, using litigation leverage to secure exclusivity-like market control.

Signal from ongoing litigation: continuing the case (as opposed to dismissing or limiting claims early) generally indicates Azurity sees enough claim/validity traction to justify cost and risk. The strength metric in practice comes from:

• Claim construction plausibility
• Prior art position on obviousness/non-enablement
• Whether Teva can change product design without substantial cost or regulatory redesign

---

Which Teva products and stakeholders are implicated? The caption lists Teva Pharmaceuticals, Inc. Teva litigation typically reflects one or more of:

• The ANDA holder entity
• A specific label/strength combination
• An identified manufacturer and/or contract manufacturer in the infringement proof

Why this matters: if the asserted product relies on a particular formulation approach, Teva’s ability to switch suppliers, processes, or manufacturing sites can drive “freedom to operate” calculations for other generic competitors.

---

What defenses are typically available to Teva in this type of case? Standard Teva defenses in Hatch-Waxman patent litigation include:

• Non-infringement: Teva argues its ANDA product does not meet claim limitations under claim construction.
• Invalidity:
  • anticipation under 35 USC § 102
  • obviousness under 35 USC § 103
  • lack of written description or enablement under 35 USC § 112
• Prosecution history estoppel: limitation-based arguments from prior amendments
• Patent misuse / inequitable conduct: less common, but sometimes asserted

Settlement drivers: if Teva’s defenses hinge on expert-dependent factual disputes (e.g., composition attributes, process parameters), parties may prefer a negotiated license rather than trial.

---

Does the case include FDA regulatory outcomes or Orange Book updates? Hatch-Waxman litigation can trigger:

• Court-ordered injunctions affecting FDA approval timing
• Settlement agreements reflected in entry “carve-out” dates
• Possible updates to Orange Book listings (additions/removals), though changes can occur independently of litigation

Key business lens: Orange Book status plus litigation posture drive market timing. If the patents are still listed at the time of generic launch, a generic launch may still be blocked unless a settlement or final judgment removes the obstacle.

---

Settlement risk: what do typical resolutions look like for Azurity v. Teva cases? Most branded-vs-generic resolutions in this space fall into these categories:

• Dismissal/withdrawal: Teva abandons the ANDA certification or the brand dismisses claims.
• Consent judgment: a negotiated outcome that may include non-infringement findings for specific claims.
• Settlement with license: Teva gains entry at a defined date, sometimes with label or formulation carve-outs.
• At-risk entry: Teva launches before full resolution if it believes patents are invalid and litigation is unfavorable to injunction.
• Injunction: Azurity obtains injunctive relief, blocking launch pending appeal.

Business implication: the most valuable commercial number is the effective entry date Teva can realize in the US, net of any 30-month stay and court outcomes.

---

How does this litigation affect the competitive landscape for generics? The practical effect extends beyond Teva:

• It can deter other ANDA filers by signaling the branded patent estate is enforceable.
• It can shape later “design-around” decisions by competitors watching how Teva argues non-infringement and invalidity.
• It can influence pricing and market share dynamics if Teva is the only or first plausible challenger.

---

Key takeaways

• Azurity Pharmaceuticals, Inc. v. Teva Pharmaceuticals, Inc. (1:23-cv-01080) is a US patent enforcement action that directly impacts Teva’s ability to launch a generic product tied to Azurity’s Orange Book-linked patents.
• The litigation strategy is aligned with Hatch-Waxman enforcement and usually hinges on claim construction, infringement mapping to Teva’s ANDA product, and validity challenges.
• The case’s economic impact is measured by (1) whether any asserted patents survive, (2) whether an injunction or settlement delays entry, and (3) how quickly the court resolves key dispositive issues.

---

FAQs

1) What is typically the fastest driver of outcomes in brand-vs-generic cases like Azurity v. Teva?
Claim construction and early dispositive rulings on validity and infringement.

2) How do settlement dates translate into effective US generic launch timing?
They define the “carve-out” entry date and any label/formulation restrictions that limit competition until then.

3) What legal theory most often determines whether a generic “design-around” works?
Claim scope under construction, especially for formulation and dosage-form limitations.

4) Do method-of-use claims require label changes to avoid infringement?
Yes, and the litigation usually turns on whether the generic label omits patented steps clearly enough.

5) Does a Paragraph IV certification always trigger a 30-month stay?
Not in every scenario; stay applicability depends on FDA timing and litigation milestones.

---

References (APA)

1. Azurity Pharmaceuticals, Inc. v. Teva Pharmaceuticals, Inc., No. 1:23-cv-01080 (U.S. District Court filing and docket).